1[1]Second Chinese Cardiac Study (CCS-2) Collaborative Group. Rational, design and organization of the Second Chinese Cardiac Study (CCS-2): A randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. J Cardiovasc Risk,2000,7:435-441.
2[2]ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet,1995,345:669-685.
3[3]Antman E M, Lau J, Kupelnick B, et al. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts: Treatments for myocardial infarction. JAMA,1992,327:248-254.
4[4]The Heart Outcome Prevention Evaluation (HOPE) Study Investigator. Effects of an angiotensin-converting enzyme inhibitor ramipril on cardiovascular events in high-risk patients. N Engl J Med,2000,342:145-153.
5[5]Freemantle N, Cleland J, Young P, Harrison, et al. b-blockade after myocardial infarction: Systematic review and meta regression analysis. BMJ,1999,318:1730-1737.
6[6]MRc/BHF Heart Protection Study Collaborative Group. Randomized trial of cholesterol-lowering with simvastatin in a wide range of patients at increased risk of vascular disease. Lancet ,2002,360:7-22.
